Meeting
2013 ASCO Annual Meeting
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
Authors
Scott D. Patterson
Amgen, Inc., Thousand Oaks, CA
Scott D. Patterson , Marc Peeters , Salvatore Siena , Eric Van Cutsem , Yves Humblet , Jean-Luc Van Laethem , Thierry Andre , Ying Tian , Roger Sidhu , Kelly S. Oliner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00113763
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3617)
DOI
10.1200/jco.2013.31.15_suppl.3617
Abstract #
3617
Poster Bd #
11C
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
First Author: K. Oliner
Poster
2019 Gastrointestinal Cancers Symposium
Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.
First Author: Jonathan M. Loree
Poster
2017 ASCO Annual Meeting
Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim